Edgewise: breaking away from dystrophin for muscular dystrophy

Edgewise emerges from stealth with $50M series B, dystrophin-independent muscle-stabilizing compounds

With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy.

Edgewise Therapeutics emerged from stealth this month with a $50 million series B round co-led by Novo Holdings A/S and U.S. Venture Partners and a portfolio of internally developed small molecule therapies for musculoskeletal indications including Duchenne and Becker muscular dystrophy.

Cure Duchenne Ventures, Deerfield Management, New Leaf

Read the full 695 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE